Kras Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 17-07-2024
- Paid Up Capital ₹ 1.50 Cr
as on 17-07-2024
- Company Age 39 Year, 10 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.44 Cr
as on 17-07-2024
- Revenue 51.47%
(FY 2022)
- Profit 34.41%
(FY 2022)
- Ebitda 563.79%
(FY 2022)
- Net Worth 2.15%
(FY 2022)
- Total Assets 34.82%
(FY 2022)
About Kras Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.50 Cr.
The company currently has active open charges totaling ₹1.44 Cr.
The Key Managerial Personnel (KMP) at Kras Pharmaceuticals Private Limited India is Rupesh Kumar as CEO. Ravi Shankar, Rupesh Kumar, and Vinita Bhushan serve as directors at the Company.
- CIN/LLPIN
U00304BR1985PTC002219
- Company No.
002219
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Sep 1985
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Company Details
- Location
Fatuha, Bihar, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Kras Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rupesh Kumar | CEO | 21-Feb-2020 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravi Shankar  | Director | 02-Jan-2019 | Current |
| Vinita Bhushan | Director | 01-Jul-2016 | Current |
Financial Performance and Corporate Structure Insights of Kras Pharmaceuticals.
Kras Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 51.47% increase. The company also saw a substantial improvement in profitability, with a 34.41% increase in profit. The company's net worth moved up by a moderate rise of 2.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kras Pharmaceuticals?
In 2021, Kras Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Venus Lifescience Private Limited.
Active
17 years 9 months Ravi Shankar, Rupesh Kumar and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 09 Sep 2022 | ₹1.20 Cr | Open |
Indian Bank Creation Date: 29 Dec 2021 | ₹2.38 M | Open |
How Many Employees Work at Kras Pharmaceuticals?
Unlock and access historical data on people associated with Kras Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
As of Mar 15, 2017, Kras Pharmaceuticals has raised a total of ₹ 3.69 M, with the most recent deal valued at ₹ 3 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
